Versatope Therapeutics, Inc.
- Universal influenza vaccine
- Cancer drug delivery
Versatope's vision is to create a healthier world with immunotherapeutics and vaccines. Versatope has a unique platform technology that could transform the way the bio-pharmaceutical industry solves problems in drug and therapeutic delivery. In five years, the company plans to have two products in the clinic, a universal influenza vaccine that protects against multiple strains of influenza and a cancer therapeutic that improves the survival of cancer patients.
Versatope has a worldwide, exclusive license to the technology invented by two professors at Cornell University, David Putnam and Matthew DeLisa of the Department of Bioengineering. The company’s foundational technology is licensed from Cornell University.